The quest to unlock RNAi's full therapeutic potential just got a significant boost. City Therapeutics, a biotech firm founded by pioneering executives and scientists in the field, has secured $99.5M in Series B funding.
The company is focused on advancing next-generation engineering of small interfering RNAs (siRNAs) – the "trigger" molecules that mediate RNAi. This capital will fuel City Therapeutics' mission to improve and expand the reach of RNAi-based medicines, building a leading company in the space to help patients with a wide range of diseases.
